

# Hong-Jae Chon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5735992/publications.pdf>

Version: 2024-02-01

56  
papers

1,880  
citations

304743

22  
h-index

302126

39  
g-index

56  
all docs

56  
docs citations

56  
times ranked

2716  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1475-1485.	7.7	306
2	STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. <i>Journal of Clinical Investigation</i> , 2019, 129, 4350-4364.	8.2	178
3	Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. <i>BMC Cancer</i> , 2016, 16, 434.	2.6	124
4	Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 74, 350-359.	3.7	122
5	Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2019, 25, 1612-1623.	7.0	120
6	Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma. <i>Annals of Surgery</i> , 2017, 265, 946-953.	4.2	117
7	STING signaling is a potential immunotherapeutic target in colorectal cancer. <i>Journal of Cancer</i> , 2019, 10, 4932-4938.	2.5	51
8	STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer. , 2021, 9, e002195.		49
9	Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. <i>BMC Cancer</i> , 2016, 16, 385.	2.6	46
10	Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9414.	4.1	46
11	Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis. <i>Liver Cancer</i> , 2020, 9, 613-624.	7.7	45
12	Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 674-681.	3.9	39
13	Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer. , 2020, 8, e000857.		37
14	Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7743.	4.1	36
15	Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. <i>Cancers</i> , 2022, 14, 1747.	3.7	36
16	PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. <i>Oncotarget</i> , 2017, 8, 113494-113501.	1.8	34
17	Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 3123.	3.7	33
18	Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study. <i>Liver International</i> , 2020, 40, 2544-2552.	3.9	32

#	ARTICLE	IF	CITATIONS
19	Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach. International Journal of Molecular Sciences, 2021, 22, 8035.	4.1	30
20	Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987112.	3.2	27
21	Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients. Cancer, 2022, 128, 995-1003.	4.1	27
22	Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events. Liver International, 2020, 40, 2263-2271.	3.9	26
23	Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials. Cancer Research and Treatment, 2009, 41, 196.	3.0	25
24	Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer. Cancer Research and Treatment, 2017, 49, 1127-1139.	3.0	25
25	Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection. Clinical Colorectal Cancer, 2018, 17, e513-e518.	2.3	24
26	Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG). ESMO Open, 2021, 6, 100049.	4.5	21
27	Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer. Cancers, 2021, 13, 4906.	3.7	18
28	Rho GTPase RhoJ is Associated with Gastric Cancer Progression and Metastasis. Journal of Cancer, 2016, 7, 1550-1556.	2.5	16
29	The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer. Gastric Cancer, 2019, 22, 113-122.	5.3	16
30	Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1. Gene Therapy, 2021, 28, 186-198.	4.5	16
31	Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma. Apmis, 2017, 125, 223-229.	2.0	15
32	Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092342.	3.2	14
33	High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer. , 2021, 9, e003353.		14
34	The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. Annals of Surgical Oncology, 2015, 22, 3938-3945.	1.5	13
35	Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110359.	3.2	13
36	High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2051-2059.	2.5	12

#	ARTICLE	IF	CITATIONS
37	The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211132.	3.2	10
38	Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?. <i>Cancers</i> , 2022, 14, 3213.	3.7	10
39	Robotic transduodenal ampullectomy: A novel minimally invasive approach for ampullary neoplasms. <i>International Journal of Medical Robotics and Computer Assisted Surgery</i> , 2019, 15, e1979.	2.3	8
40	Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210979.	3.2	7
41	Optimal Voltage and Electrical Pulse Conditions for Electrical Ablation to Induce Immunogenic Cell Death (ICD). <i>Journal of Industrial and Engineering Chemistry</i> , 2021, 94, 225-232.	5.8	6
42	Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10565-10565.	1.6	6
43	Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway. <i>Oncolmunology</i> , 2021, 10, 2005280.	4.6	6
44	Early safety from a phase I, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into liver tumors in combination with pembrolizumab (pem).. <i>Journal of Clinical Oncology</i> , 2020, 38, 3015-3015.	1.6	5
45	Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 991-999.	2.3	4
46	A phase II trial of trastuzumab plus modified-FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer (BTC): Multi-institutional study of the Korean Cancer Study Group (KCSG-HB19-14).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4161-TPS4161.	1.6	4
47	Abstract 1914: Orally available oncolytic reovirus, RC402, effectively promotes anti-cancer immunity and synergizes with immune checkpoint blockade in colon cancer. , 2021, , .		3
48	A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naïve or opioid-resistant patients. <i>Supportive Care in Cancer</i> , 2022, 30, 6103-6112.	2.2	3
49	Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. <i>European Journal of Cancer</i> , 2019, 112, 20-28.	2.8	2
50	REACH-2: first biomarker-based anti-angiogenic therapy in patients with advanced hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2020, 9, 58-58.	1.2	1
51	Efficacy and safety of second-line nab-paclitaxel plus gemcitabine (nab-P+GEM) after progression on first-line FOLFIRINOX in advanced pancreatic ductal adenocarcinoma (PDAC): Multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 689-689.	1.6	1
52	Multicenter retrospective analysis for efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU/leucovorin (5-FU/LV) after progression on gemcitabine-based therapy in Korean patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A study by Korean Cancer Study Group (KCSG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 344-344.	1.6	1
53	Characterization of hyperprogressive disease in patients with advanced biliary tract cancer treated with anti-PD-1 inhibitor: A multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 339-339.	1.6	0
54	Modeling post-progression survival in patients with HER2-positive metastatic gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15020-e15020.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Prognostic impact of different FDG-PET uptake according to histology in advanced gastric cancer.. Journal of Clinical Oncology, 2015, 33, 4113-4113.	1.6	0
56	Efficacy and safety of lenvatinib (LEN) in Korean patients (pts) with advanced hepatocellular carcinoma (aHCC): Multicenter retrospective analysis.. Journal of Clinical Oncology, 2020, 38, 490-490.	1.6	0